Dr. Ranjita Shegokar

Free University of Berlin, Germany

Email: ranjita@arcsindia.com

Qualifications

2010 Ph.D., SNDT University, India

2003 M.Sc., SNDT University, India

2001 B.Sc., BAMU University, India

Publications (selected)

1. Shegokar R., et al., Carotenoid lutein: a promising candidate for Pharmaceutical, nutraceutical and cosmeceutical application, Journal of Dietary supplements, 2012, 9(3):183-210.
2. Shegokar R., et al., Preparation, characterization of cell base delivery of surface modified stavudine lipid nanoparticles, Journal of Nanomedicine and Biotherapeutic Discovery, 2012, 1: 192. doi:10.4172/scientificreports.192.
3. Doktorovova S., Shegokar R., et al., Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN), European Journal of Pharmaceutical Sciences, 2012 Apr 11;45(5):606-12.
4. Kakran M., Shegokar R., et al., Fabrication of quercetin nanocrystals: comparison of different methods, European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80 (1), 113-21.
5. Shegokar R., et al., Surface modified nevirapine nanosuspension for HIV viral reservoir targeting: in vitro and in vivo evaluation, International Journal of Pharmaceutics, 2011, 421(2):341-52.
6. Shegokar R., et al., Nevirapine nanosuspension: comparative investigation of production methods, Nanotechnology Development, 2011, 1:e4: 16-22.
7. Doktorovova S., Shegokar R., et al., Cationic solid lipid nanoparticles (cSLN) –structure, stability and DNA binding capacity correlation, International Journal of Pharmaceutics, 2011, 420 (2), 341-349.
8. Mitri K., Shegokar R., et al., Lutein nanocrystals as antioxidant formulation for oral and dermal delivery, International Journal of Pharmaceutics, 2011, 420 (1), 141-146.
9. Al Shaal L., Shegokar R., et al., Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation, International Journal of Pharmaceutics, 2011, 420 (1), 133-140.
10. Mitri K., Shegokar R., et al., Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performances, International Journal of Pharmaceutics, 2011, 414 (1-2), 267-275.
11. Shegokar R., et al., Present status of nanoparticle research for treatment of tuberculosis, Journal of Pharmacy & Pharmaceutical Sciences, 2011, 14 (1), 100-116.
12. Shegokar R., et al., Development of nevirapine nanosuspensions for HIV chemotherapy, Die Pharmazie, 2011, 66 (6), 408-15.Shegokar R., et al., Delivery of SiRNA: role of carrier systems, Die Pharmazie, 2011, 66 (5), 313-318.
13. Shegokar R., et al., Stavudine entrapped lipid nanoparticles for targeting lymphatic HIV reservoirs, Die Pharmazie, 2011, 66 (4), 264-271.
14. Shegokar R., et al., Production & stability of stavudine solid lipid nanoparticles - from lab to industrial scale, International Journal of Pharmaceutics, 2011, 416 (2), 461-470.
15. Shegokar R., et al., In vitro protein adsorption studies on nevirapine nanosuspensions for HIV chemotherapy, Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 333–340.Al Shaal L., Müller R. H., Shegokar R., Apigenin nanosuspensions: lab scale to pilot scale, Die Pharmazie, 2010, 65 (12), 877-884.
16. Shegokar R., et al., NanoCrystals: industrially feasible multifunctional formulation technology for poorly soluble actives, International Journal of Pharmaceutics, 2010, 399 (1-2), 129-139.